JA Iribarren

Hodgkin and non‐Hodgkin lymphomas in the post‐antiretroviral therapy era according to HIV virological suppression

Teresa Aldámiz‐Echevarria, Francisco Tejerina, Chiara Fanciulli, Cristina Diez et autres

OBJECTIVES: Lymphomas remain among the most frequent HIV-associated malignancies, with risk persisting despite effective virological control. This study describes the clinical, epidemiological and prognostic characteristics of lymphomas (both Hodgkin [HL] and non-Hodgkin [NHL]) in people living with HIV (PLWH), according to virological …

es (code pays fourni par la source)

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007–2023)

Paloma Muñoz Báez, Marta Illescas López, Adolfo de Salazar, Iker Falces Romero et autres

Background: While surveillance drug resistance mutations (SDRMs) remain essential for monitoring transmitted drug resistance (TDR), the clinical impact of transmitted resistance for current first-line regimens has become increasingly important. We aimed to update estimates of TDR in Spain and assess its clinical …

es (code pays fourni par la source)

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Erkki Lathouwers, Eric Wong, Kimberley Brown, Bryan Baugh et autres

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic …

be, us (code pays fourni par la source)

Episodios de endocarditis infecciosa (EI) en pacientes con infección por VIH [VI Congreso SEICAV 2017]

Xabier Kortajarena, Má Goenaga, M Ibarguren, Harkaitz Azkune et autres

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo, José Ramón Arribas et autres

gb, fr, es, us, be (code pays fourni par la source)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients

Juan Macı́as, Josep Mallolas, López-Cortés Lf, JA Cartón et autres

7-11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

es (code pays fourni par la source)

Safety and efficacy of lopinavir/ritonavir compared to nelfinavir-based HAART during pregnancy

JM Peña, M. Guerra González, Pascual-Pareja Jf, José López-Aldeguer et autres

Purpose of the studyTo compare the safety and efficacy of lopinavir/ritonavir and nelfinavir-based regimens in HIV-1 infected pregnant women.from

es (code pays fourni par la source)

Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain

D Nieves, JA Iribarren, Antonio Rivero, Laura García-Bujalance et autres

Purpose of the study The nucleoside reverse transcriptase inhibitor abacavir is prescribed, in combination with other drugs, for the treatment of HIV-1. Roughly 4–8% of patients receiving abacavir experience a hypersensitivity reaction (HSR), which usually appears within 6 weeks of treatment initiation. …

es (code pays fourni par la source)

Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies

Francisco Rodríguez-Arrondo, Koldo Aguirrebengoa, J. Portu, José Muñóz et autres

of results 229 patients (pts) were included. Mean age was 37 years. Most pts (54%) were former intravenous drug users. 135 individuals were co-infected with HCV. Median time on NVP was 72.6 months. The main reasons to use NVP were: second or …

es (code pays fourni par la source)

Health-Related Quality of Life in HIV Patients Switching to Twice-Daily Indinavir/Ritonavir Regimen or Continuing with Three-Times-Daily Indinavir-Based Therapy

Xavier Badı́a, Daniel Podzamczer, Irene Moral, Montse Roset et autres

OBJECTIVE: To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen. METHODS: Patients on HAART including indinavir three-times-daily with undetectable viral load were randomly …

es, ar (code pays fourni par la source)

[Multiple abscesses (cerebral, splenic, cutaneous) and pulmonary infection].

X Camino, Francisco Rodríguez-Arrondo, Jon Arrizabalaga, JA Iribarren et autres

cl (code pays fourni par la source)

[Fever and petechiae developing over several days].

M A von Wichmann, Francisco Rodríguez Arrondo, JA Iribarren, Jon Arrizabalaga et autres

es (code pays fourni par la source)